Keeping in mind the considerable difference in the percentage of HR-driven tumors between HER2-low and HER2-0 BC, favoring the former, elucidating the true effect of HER2 low expression on the clinical course and outcomes could prove to be rather challenging, as nicely pointed out by Nicolo et al. [40]. The gene discussed is ERBB2; the disease is breast cancer.